Adenosine A2B Receptor Neurons

Adenosine A2B Receptor Neurons

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2B Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Adenosine A2B Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Adenosine A2B Receptor (A2BR) Neurons are neuronal populations that [@a2br-neurons]express the adenosine A2B receptor, a G protein-coupled receptor that couples to Gαs proteins and stimulates adenylate cyclase activity, increasing intracellular cAMP levels. While the A2B receptor has lower affinity for adenosine than the A1 and A2A receptors, requiring micromolar concentrations for activation, it plays critical roles in neuronal function under conditions of metabolic stress, inflammation, and hypoxia—states that are prevalent in neurodegenerative diseases PMID: 29956023(https://pubmed.ncbi.nlm.nih.gov/29956023/).

Unlike the well-characterized A2A receptors enriched in the striatum, A2B receptor expression in neurons is more widespread but at lower density. The receptor becomes particularly important during pathological conditions when adenosine concentrations rise dramatically from basal nanomolar levels to micromolar concentrations. This review covers the molecular biology of neuronal A2B receptors, their contribution to neurodegeneration, and therapeutic implications PMID: 30395318(https://pubmed.ncbi.nlm.nih.gov/30395318/).

Molecular Biology of the A2B Receptor

Gene and Protein Structure

Adenosine A2B Receptor Neurons

Overview

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2B Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Adenosine A2B Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>

Adenosine A2B Receptor (A2BR) Neurons are neuronal populations that [@a2br-neurons]express the adenosine A2B receptor, a G protein-coupled receptor that couples to Gαs proteins and stimulates adenylate cyclase activity, increasing intracellular cAMP levels. While the A2B receptor has lower affinity for adenosine than the A1 and A2A receptors, requiring micromolar concentrations for activation, it plays critical roles in neuronal function under conditions of metabolic stress, inflammation, and hypoxia—states that are prevalent in neurodegenerative diseases PMID: 29956023(https://pubmed.ncbi.nlm.nih.gov/29956023/).

Unlike the well-characterized A2A receptors enriched in the striatum, A2B receptor expression in neurons is more widespread but at lower density. The receptor becomes particularly important during pathological conditions when adenosine concentrations rise dramatically from basal nanomolar levels to micromolar concentrations. This review covers the molecular biology of neuronal A2B receptors, their contribution to neurodegeneration, and therapeutic implications PMID: 30395318(https://pubmed.ncbi.nlm.nih.gov/30395318/).

Molecular Biology of the A2B Receptor

Gene and Protein Structure

The ADORA2B gene (Adenosine A2b Receptor) is located on chromosome 17q11.2 and encodes a 332-amino acid protein belonging to the G protein-coupled receptor (GPCR) superfamily. Like other adenosine receptors, A2BR contains seven transmembrane domains connected by three extracellular and three intracellular loops. The receptor binds adenosine through interactions with residues in the transmembrane domains, particularly TM3, TM5, and TM7[@pharmacology] PMID: 28957622(https://pubmed.ncbi.nlm.nih.gov/28957622/).

The protein undergoes standard GPCR trafficking, with N-linked glycosylation in the extracellular loops affecting receptor maturation and cell surface expression. Post-translational modifications include palmitoylation at cysteine residues in the C-terminal tail, which influences receptor localization and signaling.

Signaling Pathways

A2B receptors primarily couple[@metabolism] to Gαs proteins, stimulating adenylate cyclase and increasing intracellular cAMP. However, they can also couple to Gαq proteins, activating phospholipase C and generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This dual signaling capacity allows A2BR to modulate multiple downstream effectors:

• cAMP/PKA pathway: Increased cAMP activates protein kinase A (PKA), which phosphorylates numerous targets including CREB (cAMP response element-binding protein), modulating gene transcription
• MAPK pathway: cAMP can activate the Ras/Raf/MEK/ERK cascade, influencing cell proliferation and survival
• PI3K/Akt pathway: A2BR can activate PI3K signaling, promoting cell survival
• PLC pathway: Gαq coupling activates phospholipase C, mobilizing calcium stores

Expression in the Central Nervous System

Neuronal Expression Patterns

A2B receptor expression in neurons is more modest compared to glial cells but becomes significant under pathological conditions. Studies using immunohistochemistry and in situ hybridization have detected A2BR mRNA and protein in:

• Hippocampal neurons: Particularly in CA1 and CA3 regions, with expression in both pyramidal neurons and interneurons
• Cerebral cortex: Layer II/III pyramidal neurons and interneurons
• Cerebellar Purkinje cells: Moderate expression
• Subcortical structures: Hypothalamic nuclei and certain thalamic relay neurons

• Chronic neuroinflammation: Pro-inflammatory cytokines increase A2BR expression
• Ischemia and hypoxia: Hypoxia-inducible factor (HIF) signaling directly upregulates ADORA2B transcription
• Aging: A2BR expression increases in aged brain tissue
• Neurodegenerative pathology: Aβ and α-synuclein aggregation drive A2BR upregulation

Glial A2B Receptor Expression

While this page focuses on neurons, understanding glial A2BR is essential for the neuronal context, as neuron-glia crosstalk heavily involves adenosine signaling:

• Astrocytes: Express high levels of A2BR, particularly when reactive. A2BR activation in astrocytes promotes inflammatory cytokine release and affects astrocyte metabolic support to neurons PMID: 25387617(https://pubmed.ncbi.nlm.nih.gov/25387617/)
• Microglia: Express A2BR that modulates their inflammatory phenotype. A2BR activation generally promotes pro-inflammatory microglial activation PMID: 26254520(https://pubmed.ncbi.nlm.nih.gov/26254520/)
• Oligodendrocytes: Express A2BR affecting their viability and myelination capacity

Role in Neurodegenerative Diseases

Alzheimer's Disease

A2B receptors play complex roles in Alzheimer's disease pathogenesis:

Amyloid-β Interactions

A2BR activation modulates amyloid-β (Aβ) pathology through multiple mechanisms PMID: 30395318(https://pubmed.ncbi.nlm.nih.gov/30395318/):

• A2BR activation promotes Aβ production by enhancing γ-secretase activity
• A2BR signaling increases expression of amyloid precursor protein (APP)
• In contrast, A2BR blockade reduces Aβ accumulation in APP/PS1 mouse models

A2BR on neurons and glia contributes to neuroinflammation in AD:

• A2BR activation in astrocytes increases IL-1β, TNF-α, and IL-6 release
• Neuronal A2BR signaling enhances excitotoxicity when overactivated
• A2BR contributes to chronic neuroinflammation that drives disease progression

A2BR signaling affects learning and memory PMID: 24882564(https://pubmed.ncbi.nlm.nih.gov/24882564/):

• A2BR activation in hippocampal neurons impairs long-term potentiation (LTP)
• A2BR blockade enhances memory in AD mouse models
• The receptor may contribute to memory deficits through cAMP-mediated signaling that disrupts synaptic plasticity

Parkinson's Disease

A2B receptors are implicated in Parkinson's disease through several mechanisms PMID: 28139685(https://pubmed.ncbi.nlm.nih.gov/28139685/):

Dopaminergic Neuron Vulnerability

• A2BR expression increases in dopaminergic neurons in PD models
• A2BR activation promotes oxidative stress in dopaminergic neurons
• The receptor may contribute to neuroinflammation in the substantia nigra

• A2BR on microglia promotes pro-inflammatory responses that damage dopaminergic neurons
• Astrocyte A2BR activation affects their support of neuronal survival
• A2BR contributes to neuroinflammation that drives disease progression

A2A receptor antagonists (e.g., istradefylline) are approved for PD, and A2BR may provide additional therapeutic targets:

• A2BR antagonists could reduce neuroinflammation
• Combined A2A/A2B blockade might provide enhanced benefit

Stroke and Ischemia

A2B receptors play significant roles in cerebral ischemia PMID: 22935394(https://pubmed.ncbi.nlm.nih.gov/22935394/):

Hypoxia Response

• A2BR is strongly upregulated during hypoxic conditions through HIF-1α mediated transcription
• A2BR activation promotes angiogenic responses
• The receptor contributes to blood-brain barrier dysfunction post-ischemia

• Acute A2BR activation can be protective through cAMP-mediated pro-survival signaling
• Chronic A2BR activation promotes inflammation and exacerbates damage
• Timing and duration of activation determine the net effect

Epilepsy

A2B receptors are implicated in epileptogenesis PMID: 25449776(https://pubmed.ncbi.nlm.nih.gov/25449776/):

• A2BR expression increases in epileptic hippocampus
• A2BR activation promotes seizure activity through enhanced neuronal excitability
• A2BR antagonists may have anti-epileptogenic potential
• The receptor modulates neuroinflammation that contributes to seizure generation

Amyotrophic Lateral Sclerosis

A2B receptors are being studied in ALS:

• A2BR expression is altered in ALS motor cortex
• The receptor may contribute to excitotoxicity in motor neurons
• A2BR antagonists could provide neuroprotective effects
• Interactions with astrocyte dysfunction in ALS

Multiple Sclerosis

• A2BR on glial cells contributes to demyelination
• Modulation of immune cell trafficking across BBB
• Potential for A2BR targeting in neuroinflammation

Cellular Mechanisms of A2BR-Mediated Neurodegeneration

Calcium Dysregulation

A2B receptor signaling affects intracellular calcium homeostasis:

• Gαq coupling leads to IP3-mediated calcium release from ER stores
• Elevated intracellular calcium can trigger apoptotic pathways
• A2BR activation sensitizes neurons to excitotoxic cell death
• Calcium dysregulation contributes to mitochondrial dysfunction

Oxidative Stress

A2BR activation promotes oxidative stress in neurons:

• Increased mitochondrial ROS production
• Reduced antioxidant enzyme expression
• Activation of NADPH oxidase in glia
• Cross-talk with neuroinflammation amplifies oxidative damage

Mitochondrial Dysfunction

A2BR signaling affects mitochondrial health:

• Altered mitochondrial dynamics (fusion/fission)
• Impaired mitophagy and mitofusion
• Decreased ATP production
• Membrane potential depolarization
• Release of pro-apoptotic factors

Endoplasmic Reticulum Stress

A2BR activation can induce ER stress:

• Upregulation of CHOP and other ER stress markers
• Activation of unfolded protein response (UPR)
• Disruption of calcium homeostasis
• Contribution to protein aggregation

Autophagy Dysregulation

A2BR modulates autophagy:

• mTOR pathway involvement
• Effects on lysosomal function
• Impaired clearance of protein aggregates
• Interaction with p62/SQSTM1 signaling

Animal Models and Experimental Evidence

Genetic Models

Several genetic models have been used to study A2BR:

• ADORA2B knockout mice: Reveal A2BR's role in hypoxia response
• Conditional knockout: Cell-type specific deletion to assess neuronal vs. glial contributions
• Transgenic overexpression: A2BR overexpression models to assess disease progression

Pharmacological Models

• A2BR agonists (e.g., BAY 60-6583): Used to assess acute and chronic effects
• A2BR antagonists (e.g., PSB 1115): Used to block receptor signaling
• Selectivity challenges complicate interpretation

Disease Models

• Alzheimer's models: APP/PS1, 5xFAD crossed with A2BR mutants
• Parkinson's models: MPTP, 6-OHDA with A2BR modulation
• Stroke models: MCAO with A2BR agonist/antagonist treatment
• Epilepsy models: Kainic acid, PTZ with A2BR targeting

Synaptic Function and Plasticity

Effects on Synaptic Transmission

A2B receptors modulate synaptic transmission through several mechanisms PMID: 25656175(https://pubmed.ncbi.nlm.nih.gov/25656175/):

Presynaptic Effects

• A2BR activation can modulate neurotransmitter release
• The receptor affects presynaptic calcium dynamics
• Modulation of vesicular release depends on cAMP levels

• A2BR activation modulates postsynaptic cAMP levels
• Affects NMDA receptor function and trafficking
• Influences AMPA receptor trafficking

Long-Term Potentiation and Depression

A2BR signaling impacts synaptic plasticity:

• LTP: A2BR activation can impair LTP induction in hippocampal neurons
• LTD: A2BR signaling promotes certain forms of LTD
• The net effect depends on the brain region and specific synaptic circuits

Therapeutic Targeting

A2B Receptor Agonists

A2B receptor agonists have been developed for various applications PMID: 25323126(https://pubmed.ncbi.nlm.nih.gov/25323126/):

Development Status

• Multiple A2BR agonists have entered clinical trials
• Focus on peripheral inflammatory conditions
• CNS penetration remains a challenge

• Acute neuroprotection in stroke
• Promotion of tissue repair
• Enhancement of cognitive function (possible)

A2B Receptor Antagonists

A2BR antagonists are being developed for neurodegenerative applications PMID: 28957622(https://pubmed.ncbi.nlm.nih.gov/28957622/):

Rationale

• Reduce neuroinflammation
• Block Aβ-induced toxicity
• Protect dopaminergic neurons in PD
• Prevent excitotoxicity

• Achieving adequate brain penetration
• Selectivity over other adenosine receptors
• Timing of intervention

Biomarker Potential

A2B receptors have potential as biomarkers in neurodegenerative diseases PMID: 28139685(https://pubmed.ncbi.nlm.nih.gov/28139685/):

Imaging Biomarkers

• PET ligands for A2BR are under development
• Could visualize neuroinflammation in vivo
• May track disease progression

Fluid Biomarkers

• A2BR expression on neural-derived exosomes
• CSF A2BR levels as inflammatory marker
• Blood-brain barrier A2BR as vascular dysfunction marker

Aging and A2B Receptors

A2B receptor expression and function change with aging PMID: 25092682(https://pubmed.ncbi.nlm.nih.gov/25092682/):

• A2BR expression increases in aged brain
• Signaling efficiency may decline
• Contributes to age-related neuroinflammation
• May represent a therapeutic target for age-related cognitive decline

Cross-Linking with Related Pathways

Purinergic Signaling

• A2BR is part of the broader purinergic signaling network
• Interactions with P2X and P2Y receptors
• ATP release and extracellular metabolism to adenosine

Neuroinflammation

• A2BR is a key modulator of neuroinflammation
• Cross-talk with cytokine signaling pathways
• Interactions with microglial activation states

Metabolism and Energy

• A2BR links cellular energy status to function
• Adenosine as an energy sensor
• Effects on glucose metabolism and mitochondrial function

Research Directions

Unanswered Questions

Emerging Areas

Clinical Trials and Therapeutic Development

Current Clinical Landscape

Several clinical trials have investigated adenosine receptor targeting in neurodegenerative diseases:

A2A Receptor Antagonists (Approved)

• Istradefylline (KW-6002): Approved in Japan (2009) for Parkinson's disease "off" periods. Works by blocking A2A receptors, not A2B.
• Clinical trials in US/EU did not meet primary endpoints

• No A2B-specific compounds have reached late-stage clinical trials for neurodegeneration
• Early-phase trials for peripheral inflammatory conditions have been conducted
• CNS penetration remains a major challenge

Challenges in A2BR-Targeting for Neurodegeneration

Pharmacokinetic Challenges

• Blood-brain barrier penetration is limited for most A2BR ligands
• P-glycoprotein efflux affects brain exposure
• Need for compounds with optimal lipophilicity

• A2BR ligands often have cross-reactivity with A2A and other adenosine receptors
• Achieving selectivity without losing efficacy is difficult
• Off-target effects complicate safety profiles

• Chronic vs. acute treatment may have different effects
• Disease stage affects treatment response
• Optimal intervention window unclear

Emerging Therapeutic Strategies

Allosteric Modulators

• Positive allosteric modulators (PAMs) may provide more nuanced signaling
• Lower risk of receptor desensitization
• More tissue-selective effects possible

• Nanoparticle-based delivery systems
• Focused ultrasound for BBB opening
• Prodrug strategies for brain targeting

• Viral vector-mediated A2BR modulation
• CRISPR-based targeting of ADORA2B gene
• Cell-type specific expression systems

Pathway Diagram

Summary

Adenosine A2B Receptor Neurons represent an important neuronal population in neurodegenerative disease contexts. While A2B receptor expression in neurons is modest under physiological conditions, it becomes highly significant during pathological states characterized by elevated adenosine, inflammation, or hypoxia.

Key insights include:

Understanding the cell-type-specific functions of A2BR in neurons versus glia will be critical for developing effective therapeutic strategies.

See Also

• [Adenosine Signaling in Neurodegeneration](/mechanisms/adenosine-signaling-neurodegeneration)
• [ADORA2B Gene](/genes/adora2b)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Adenosine A2A Receptor Neurons](/cell-types/adenosine-a2a-receptor-neurons)
• [Purinergic Signaling](/mechanisms/purinergic-signaling)
• [Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)

References

External Links

• [NCBI Gene - ADORA2B](https://www.ncbi.nlm.nih.gov/gene/136)
• [UniProt - A2B Receptor](https://www.uniprot.org/uniprot/P29274)
• [IUPHAR/BPS Guide - A2B Receptor](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18)
• [PubMed: A2B receptor neurons neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=adenosine+a2b+receptor+neurons+neurodegeneration)